ChemoCentryx Company Profile
ChemoCentryx, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of orally administered therapeutics to treat orphan and rare diseases, autoimmune diseases, inflammatory disorders, and cancer in the United States. Its lead drug candidates in clinical development include CCX168, which is in Phase II clinical trials for the treatment of orphan and rare diseases; CCX872, which is in Phase Ib clinical trials for the treatment of immuno-oncology diseases; and CCX140 that has completed a Phase II clinical trial for the treatment of chronic kidney diseases. The company is also developing Vercirnon, which is in Phase III clinical trials for the treatment of patients with moderate-to-severe Crohns diseases; CCX507 that has completed Phase I clinical trial for the treatment of inflammatory bowel diseases; and Th-17 cells for the treatment of psoriasis, rheumatoid arthritis, and asthma. The company was founded in 1997 and is headquartered in Mountain View, California.